NCT03555032View on ClinicalTrials.gov

TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 26, 2018

Primary Completion Date

August 1, 2021

Study Completion Date

August 1, 2021

Conditions
Melanoma and Sarcoma
Interventions
DRUG

Talimogene laherparepvec (T-VEC)

One dose of 1 x 106 PFU/mL. Two doses of 1 x 108 PFU/mL. Given by intra-tumoural (i.t.) injection.

Trial Locations (1)

SW3 6JJ

The Royal Marsden NHS Foundation Trust, London

All Listed Sponsors
lead

Royal Marsden NHS Foundation Trust

OTHER

NCT03555032 - TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion) | Biotech Hunter | Biotech Hunter